EPZM - Epizyme, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.82
+0.09 (+0.71%)
As of 1:04PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close12.73
Open12.72
Bid12.82 x 800
Ask12.86 x 1200
Day's Range12.66 - 12.99
52 Week Range5.14 - 16.59
Volume88,669
Avg. Volume890,684
Market Cap1.164B
Beta (3Y Monthly)2.06
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire7 hours ago

    Epizyme Strengthens Leadership Team with Appointment of Paolo Tombesi as Chief Financial Officer

    Mr. Tombesi brings over 30 years of extensive financial and accounting expertise to Epizyme, most recently serving as the chief financial officer at Insmed, Incorporated. “Paolo is a seasoned healthcare and financial executive with a distinguished track record of leading financial operations and strategy, overseeing capital allocation and fund raising.

  • Business Wirelast month

    Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat in Patients with Relapsed or Refractory Follicular Lymphoma

    The data show that tazemetostat demonstrated meaningful clinical activity and was generally well tolerated in both patients with EZH2 activating mutations and those with wild-type EZH2. The data will be presented today in an oral presentation entitled “Interim update from a Phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory follicular lymphoma” at the International Conference on Malignant Lymphoma (ICML) by Franck Morschhauser, M.D., Ph.D., Centre Hospitalier Régional Universitaire de Lille, France, an investigator in the Phase 2 trial.

  • Business Wirelast month

    Epizyme Announces Conference Call to Discuss Phase 2 Tazemetostat Follicular Lymphoma Data

    Epizyme, Inc. (EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that management will host a conference call on Friday, June 21, 2019 at 8:30 a.m. ET to discuss updated data from an ongoing Phase 2 study of its lead candidate, tazemetostat, as a monotherapy for patients with relapsed or refractory follicular lymphoma. The data, which will be from a recent June 2019 data cutoff date, will be reported in an oral presentation by Franck Morschhauser, M.D., Ph.D., Centre Hospitalier Régional Universitaire and study investigator, at the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland.

  • Business Wire2 months ago

    Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat for Epithelioid Sarcoma at 2019 ASCO Annual Meeting

    The data will be presented today in an oral presentation entitled “Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients with epithelioid sarcoma” at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting by Silvia Stacchiotti, M.D., Fondazione IRCCS Istituto Nazionale Tumori, Milan, and an investigator in the Phase 2 clinical trial. In July 2017, Epizyme completed enrollment of 62 patients in the epithelioid sarcoma cohort of its Phase 2 trial.

  • Business Wire2 months ago

    Epizyme Submits New Drug Application to the U.S. FDA for Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma

    Epizyme, Inc. (EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of tazemetostat for the treatment of patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery. Tazemetostat is an oral, first-in-class, EZH2 inhibitor discovered by Epizyme and being developed for a range of cancers and treatment settings.

  • Business Wire2 months ago

    Epizyme to Present at Jefferies 2019 Healthcare Conference

    Epizyme, Inc. , a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will present at the Jefferies 2019 Healthcare Conference on June 5, 2019 at 3:00 p.m.

  • Business Wire2 months ago

    Epizyme Announces New Tazemetostat Clinical Data to be Presented in Oral Sessions at Multiple Upcoming Medical Meetings

    Epizyme, Inc. (EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that new data from the epithelioid sarcoma and follicular lymphoma cohorts of the company’s ongoing Phase 2 clinical trials of tazemetostat will be reported during oral presentations at medical meetings in June. Updated data from the fully enrolled cohort of epithelioid sarcoma patients in the company’s molecularly defined solid tumor program will be presented at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting in Chicago. Updated data from the fully enrolled cohorts of patients with follicular lymphoma, both with and without EZH2 activating mutations, will be reported at the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland.

  • Business Wire3 months ago

    Epizyme Provides Business Update and Reports First Quarter 2019 Financial Results

    Tazemetostat NDA Submissions for Epithelioid Sarcoma and Follicular Lymphoma on Track for Second Quarter and Fourth Quarter 2019, Respectively

  • Business Wire4 months ago

    Epizyme Announces Closing of Concurrent Public Offerings and Full Exercise of Underwriter’s Option to Purchase Additional Shares

    Epizyme, Inc. (EPZM), a late-stage company developing novel epigenetic therapies, today announced the closing of its two concurrent underwritten public offerings of 11,500,000 shares of its common stock and 350,000 shares of its non-voting Series A Convertible Preferred Stock, which includes the full exercise by the underwriters of their separate options in each of the respective offerings to purchase additional shares at the public offering price. The public offering price of each share of common stock was $11.50 and the public offering price of each share of Series A stock was $115.00. The aggregate gross proceeds to Epizyme from the offerings, before deducting underwriting discounts and offering expenses, are $172.50 million.

  • Business Wire5 months ago

    Epizyme Announces Pricing of Concurrent Public Offerings of Common Stock and Series A Preferred Stock

    Epizyme, Inc. (EPZM), a late-stage company developing novel epigenetic therapies, today announced the pricing of two concurrent underwritten public offerings of (i) 10,000,000 shares of its common stock and (ii) 304,348 shares of its non-voting Series A Convertible Preferred Stock. Epizyme anticipates the total gross proceeds from the offering (before deducting underwriting discounts and offering expenses) will be approximately $150 million, excluding any exercise of the underwriters' options to purchase additional shares and before deducting underwriting discounts and offering expenses. The public offering price of each share of common stock is $11.50 and the public offering price of each share of Series A stock is $115.00.

  • Business Wire5 months ago

    Epizyme Announces Proposed Concurrent Public Offerings of Common Stock and Series A Preferred Stock

    Epizyme, Inc. (EPZM), a late-stage company developing novel epigenetic therapies, today announced that it intends to offer and sell shares of its common stock and Series A convertible preferred stock in two concurrent but separate underwritten public offerings. The offerings are being made by means of separate preliminary prospectus supplements and are not contingent upon each other. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock and preferred stock offered in the offering.

  • Business Wire5 months ago

    Epizyme Announces Presentations at Upcoming March Investor Conferences

    Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will present at the following March inv

  • Business Wire5 months ago

    Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results

    Two Successive Tazemetostat NDA Submissions for Epithelioid Sarcoma and Follicular Lymphoma on Track for 2019

  • Business Wire5 months ago

    Epizyme Announces Date of Fourth Quarter and Full Year 2018 Results and Upcoming Presentation at the 8th Annual SVB Leerink Global Health Care Conference

    Fourth Quarter and Full-Year 2018 Financial Results: Management will host a conference call and webcast to discuss its fourth quarter and full year 2018 financial results and other business highlights at 8:30 a.m. ET on Tuesday, February 26, 2019. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 1088195.

  • GlobeNewswire5 months ago

    New Research: Key Drivers of Growth for ON Semiconductor, Entegris, Universal, MarineMax, Epizyme, and Merrimack Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE7 months ago

    These 4 Healthcare Stocks Are Making Moves

    CORAL GABLES, FL / ACCESSWIRE / January 4, 2019 / The healthcare industry is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Synergy Pharmaceuticals Inc (SGYP), Novavax Inc (NVAX), and Epizyme Inc (EPZM) are 4 healthcare stocks representing companies invested in creating the best quality treatments for their patients. Premier Health Group (OTC:PHGRF) (CSE:PHGI) opened Friday with the Company's shares trading at $0.63 per share, well above the $0.53 close back in October, as well as steadily ahead of $0.59 per share price point from early last month.

  • Business Wire7 months ago

    Epizyme Announces Registration Path for Tazemetostat for Follicular Lymphoma and Provides Pipeline Updates and 2019 Guidance

    Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, today announced a comprehensive set of pipeline updates, including that the company has identified a path to submission for accelerated approval of tazemetostat for patients with relapsed and/or refractory follicular lymphoma (FL), both with and without EZH2 activating mutations. The company recently conducted a productive meeting with the U.S. Food and Drug Administration (FDA) to discuss the FL registration strategy based on the current patient population in its ongoing Phase 2 clinical trial.

  • Business Wire7 months ago

    Epizyme Earns $8 Million Milestone Payment from GlaxoSmithKline for Initiation of Clinical Development for First-in-Class PRMT1 Inhibitor

    Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, today announced it has earned an $8 million milestone payment from GlaxoSmithKline (GSK). The milestone payment follows GSK’s initiation of patient dosing in a Phase 1 clinical trial of GSK3368715, a first-in-class protein arginine methyltransferase1 (PRMT1) inhibitor discovered by Epizyme and licensed to GSK. “We are very pleased to see the progress that GSK has made with its PRMT1 inhibitor program, which marks the second program under our collaboration agreement to enter the clinic,” said Robert Bazemore, president and chief executive officer of Epizyme.

  • Business Wire8 months ago

    Epizyme Announces Conference Call to Discuss Corporate Updates

    Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that management will host a conference call to discuss corporate updates today at 8:30 a.m. ET. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 5172457. Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines.

  • GlobeNewswire8 months ago

    Market Trends Toward New Normal in Paramount Group, Envestnet, Assurant, HubSpot, Epizyme, and Cytosorbents — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire9 months ago

    Epizyme Reports Third Quarter 2018 Financial Results and Tazemetostat Progress

    Enrollment in Phase 2 Cohort of Follicular Lymphoma Patients with EZH2 Activating Mutations on Track to be Completed by Year End

  • Business Wire9 months ago

    Epizyme Reports Positive Data on Tazemetostat in Epithelioid Sarcoma from its Phase 2 Trial Cohort at ESMO

    Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, today announced positive interim data from the fully enrolled epithelioid sarcoma cohort of its ongoing Phase 2 study of its lead candidate tazemetostat, a potent, selective, orally available EZH2 inhibitor. The data were presented by the study’s lead investigator, Mrinal Gounder, M.D., attending physician, Sarcoma Medical Oncology and Early Drug Development Services, Memorial Sloan Kettering Cancer Center, during the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany. Interim data as of August 21, 2018 from the 62 patients enrolled show that tazemetostat treatment demonstrated clinically meaningful activity for patients with epithelioid sarcoma (ES).

  • Business Wire9 months ago

    Epizyme to Present Updated Data on Tazemetostat from Full Phase 2 Study Cohort in Epithelioid Sarcoma at ESMO

    Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, announced today that updated efficacy and safety data from the fully enrolled cohort of epithelioid sarcoma (ES) patients in its ongoing Phase 2 trial of tazemetostat will be presented in a poster discussion session at the European Society for Medical Oncology (ESMO) 2018 Congress to be held October 19-23 in Munich, Germany. Tazemetostat is the company’s potent, selective, orally available, first-in-class EZH2 inhibitor. The Phase 2 study ES cohort completed enrollment in 2017 with a total of 62 patients.

  • Business Wire10 months ago

    Epizyme Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares

    Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the closing of its underwritten public offering of 9,583,334 shares of its common stock at a public offering price of $9.00 per share, which includes 1,250,000 shares issued upon the exercise in full by the underwriter of its option to purchase additional shares at the public offering price less the underwriting discount. The aggregate gross proceeds to Epizyme from the offering, before deducting underwriting discounts and offering expenses, are $86.25 million.